| Literature DB >> 28649180 |
Artur Fedorowski1,2, Nazim Isma1,3, Viktor Hamrefors1,4,5, Karin Strandberg6, Richard Sutton7.
Abstract
BACKGROUND: Orthostatic hypercoagulability is proposed as a mechanism promoting cardiovascular and thromboembolic events after awakening and during prolonged orthostasis. We evaluated early changes in coagulation biomarkers induced by tilt testing among patients investigated for suspected syncope, aiming to test the hypothesis that orthostatic challenge evokes procoagulatory changes to a different degree according to diagnosis.Entities:
Keywords: Coagulation factors; Fibrinogen; Hypercoagulability; Orthostatic stress; Partial thromboplastin time; von Willebrand factor
Year: 2017 PMID: 28649180 PMCID: PMC5477734 DOI: 10.1186/s12959-017-0139-z
Source DB: PubMed Journal: Thromb J ISSN: 1477-9560
Characteristics and risk factors in 178 consecutive patients with unexplained syncope, mean ± SD or n (%)
| All patients | Men | Women |
| |
|---|---|---|---|---|
|
|
|
| ||
|
| ||||
| Age (years) | 50.9 ± 20.9 | 56.0 ± 18.7 | 46.6 ± 21.8 | 0.003 |
| BMI (kg/ m2) | 25.6 ± 4.6 | 26.0 ± 3.6 | 25.3 ± 5.3 | 0.34 |
| Systolic BP (mmHg) | 131 ± 18.7 | 131 ± 17.1 | 132 ± 20.0 | 0.78 |
| Diastolic BP (mmHg) | 71 ± 8.0 | 71 ± 8.8 | 70 ± 7.6 | 0.44 |
| Heart rate (bpm) | 67.7 ± 11.7 | 65.4 ± 12.7 | 69.6 ± 10.6 | 0.016 |
|
| ||||
| Hypertension | 28.8 | 35.0 | 23.7 | 0.10 |
| Diabetes mellitus | 6.7 | 8.6 | 5.2 | 0.36 |
| History of MACEa | 3.9 | 7.4 | 1.0 | 0.029 |
| History of stroke | 1.7 | 2.5 | 1.0 | 0.46 |
| Present tobacco use | 15.7 | 16.0 | 15.5 | 0.92 |
BMI, body mass index; BP, blood pressure; MACEa (=major coronary event) was defined as history of myocardial infarction, unstable angina, CABG, or PCI
Coagulation markers in supine and after 3 min head-up tilt (HUT) in 178 patients with unexplained syncope, mean ± SD or n (%)
| All patients |
| Men | Women |
| |
|---|---|---|---|---|---|
| N (%) | 178 | 81 (46) | 97 (54) | ||
| FVIII:C | 1.06 ± 0.38 | 0.43 | 1.07 ± 0.32 | 1.04 ± 0.41 | 0.56 |
| FVIII:C | 1.07 ± 0.36 | 1.07 ± 0.35 | 1.07 ± 0.36 | 0.98 | |
| VWF:Ag | 1.22 ± 0.54 | <0.001 | 1.28 ± 0.56 | 1.17 ± 0.51 | 0.17 |
| VWF:Ag | 1.28 ± 0.55 | 1.33 ± 0.59 | 1.24 ± 0.52 | 0.31 | |
| VWF:GP1bA | 1.24 ± 0.55 | 0.20 | 1.30 ± 0.59 | 1.19 ± 0.52 | 0.19 |
| VWF:GP1bA | 1.26 ± 0.56 | 1.31 ± 0.64 | 1.23 ± 0.49 | 0.34 | |
| Fibrinogen | 2.75 ± 0.60 | <0.001 | 2.67 ± 0.57 | 2.81 ± 0.62 | 0.11 |
| Fibrinogen | 2.84 ± 0.60 | 2.73 ± 0.59 | 2.93 ± 0.60 | 0.022 | |
| LA1 | 31.2 ± 3.7 | 0.066 | 31.9 ± 3.50 | 30.7 ± 3.8 | 0.027 |
| LA1 | 31.1 ± 4.7 | 32.0 ± 3.92 | 30.5 ± 5.2 | 0.030 | |
| APC-resistance | 2.60 ± 0.41 | <0.001 | 2.65 ± 0.39 | 2.57 ± 0.42 | 0.17 |
| APC-resistance | 2.42 ± 0.43 | 2.49 ± 0.41 | 2.36 ± 0.44 | 0.044 | |
| APTT/C+ | 84.3 ± 19.6 | <0.001 | 85.8 ± 19.8 | 83.1 ± 19.5 | 0.36 |
| APTT/C+ | 75.1 ± 18.8 | 77.4 ± 18.7 | 73.1 ± 18.7 | 0.13 | |
| APTT/C- | 32.1 ± 3.8 | <0.001 | 32.1 ± 4.1 | 32.1 ± 3.6 | 1.0 |
| APTT/C- | 30.8 ± 3.7 | 30.8 ± 3.8 | 30.7 ± 3.7 | 0.83 |
*supine vs. HUT paired samples t-test; ¶ men vs. women independent samples t-test; FVIII, factor VIII; VWF:Ag, von Willebrand factor antigen; vVWF:GP1bA, von Willebrand factor GP1bA activity; LA1, lupus anticoagulant-screening; APC-resistance, activated protein C resistance; APTT, activated prothrombin time; C+/−, with/without activated protein C
Gender-stratified changes in coagulation markers during head-up tilt among 178 patients with unexplained syncope
| Men |
| Women |
| |
|---|---|---|---|---|
| N (%) | 81 (46) | 97 (54) | ||
| Δ FVIII:C (kIE/L) | 0.00 ± 0.16 | 0.64 | 0.02 ± 0.13 | 0.091 |
| Δ VWF:Ag (kIE/L) | 0.04 ± 0.18 | 0.030 | 0.07 ± 0.15 | <0.001 |
| Δ VWF:GP1bA (kIE/L) | 0.01 ± 0.25 | 0.86 | 0.03 ± 0.18 | 0.067 |
| Δ Fibrinogen (g/L) | 0.06 ± 0.32 | 0.12 | 0.12 ± 0.22 | <0.001 |
| Δ LA1 (sec) | −0.13 ± 3.23 | 0.72 | −0.56 ± 1.96 | 0.007 |
| Δ APC-resistance | −0.16 ± 0.26 | <0.001 | −0.21 ± 0.26 | <0.001 |
| Δ APTT/C+ (sec) | −8.3 ± 13.7 | <0.001 | −9.9 ± 10.6 | <0.001 |
| Δ APTT/C- (sec) | −1.2 ± 2.4 | <0.001 | −1.4 ± 1.7 | <0.001 |
*supine vs. HUT paired samples t-test; FVIII, factor VIII; VWF:Ag, von Willebrand factor antigen; vWF:GP1bA, von Willebrand factor GP1bA activity; LA1, lupus anticoagulant-screening; APC-resistance, activated protein C resistance; APTT, activated prothrombin time; C+/−, with/without activated protein C
Age-stratified changes in coagulation markers during head-up tilt among 178 patients with unexplained syncope
| Age < 65 years |
| Age ≥ 65 years |
| |
|---|---|---|---|---|
| N (%) | 119 (67) | 59 (33) | ||
| Δ FVIII:C (kIE/L) | 0.02 ± 0.15 | 0.17 | −0.01 ± 0.15 | 0.55 |
| Δ VWF:Ag (kIE/L) | 0.04 ± 0.15 | 0.006 | 0.10 ± 0.19 | <0.001 |
| Δ VWF:GP1bA (kIE/L) | 0.02 ± 0.22 | 0.35 | 0.02 ± 0.19 | 0.37 |
| Δ Fibrinogen (g/L) | 0.10 ± 0.30 | <0.001 | 0.07 ± 0.20 | 0.009 |
| Δ LA1 (sec) | −0.40 ± 2.88 | 0.14 | −0.31 ± 1.92 | 0.25 |
| Δ APC-resistance | −0.16 ± 0.24 | <0.001 | −0.24 ± 0.28 | <0.001 |
| Δ APTT/C+ (sec) | −8.5 ± 12.2 | <0.001 | −10.6 ± 11.9 | <0.001 |
| Δ APTT/C- (sec) | −1.3 ± 2.1 | <0.001 | −1.3 ± 2.0 | <0.001 |
*supine vs. HUT paired samples t-test; FVIII, factor VIII; VWF:Ag, von Willebrand factor antigen; vWF:GP1bA, von Willebrand factor GP1bA activity; LA1, lupus anticoagulant-screening; APC-resistance, activated protein C resistance; APTT, activated prothrombin time; C+/−, with/without activated protein C